## CHEERS checklist—Items to include when reporting economic evaluations of health interventions

	Item		Reported on page No/
Section/item	No	Recommendation	line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use	1
		more specific terms such as "cost-effectiveness	
		analysis", and describe the interventions compared.	
Abstract	2	Provide a structured summary of objectives,	3-4
		perspective, setting, methods (including study design	
		and inputs), results (including base case and	
		uncertainty analyses), and conclusions.	
Introduction			
Background and	3	Provide an explicit statement of the broader context	6-7
objectives		for the study.	
		Present the study question and its relevance for	6-7
		health policy or practice decisions.	
Methods			
Target population and	4	Describe characteristics of the base case population	8-9
subgroups		and subgroups analysed, including why they were	
		chosen.	
Setting and location	5	State relevant aspects of the system(s) in which the	8
		decision(s) need(s) to be made.	
Study perspective	6	Describe the perspective of the study and relate this	8-14
		to the costs being evaluated.	
Comparators	7	Describe the interventions or strategies being	9-10
		compared and state why they were chosen.	
Time horizon	8	State the time horizon(s) over which costs and	8-14
		consequences are being evaluated and say why	
		appropriate.	
Discount rate	9	Report the choice of discount rate(s) used for costs	N/A
		and outcomes and say why appropriate.	
Choice of health	10	Describe what outcomes were used as the measure(s)	10-14
outcomes		of benefit in the evaluation and their relevance for	
		the type of analysis performed.	
Measurement of	11a	Single study-based estimates: Describe fully the	8-14
effectiveness		design features of the single effectiveness study and	
		why the single study was a sufficient source of clinical	
		effectiveness data.	
	11b	Synthesis-based estimates: Describe fully the methods	
		used for identification of included studies and	N/A
		synthesis of clinical effectiveness data.	
Measurement and	12	If applicable, describe the population and methods	N/A
valuation of preference		used to elicit preferences for outcomes.	
based outcomes			
Estimating resources and	13a	Single study-based economic evaluation: Describe	
costs		approaches used to estimate resource use associated	
		with the alternative interventions. Describe primary	
		or secondary research methods for valuing each	12-14
		resource item in terms of its unit cost. Describe any	
		adjustments made to approximate to opportunity	
	124	costs.	
	13b	Model-based economic evaluation: Describe	NI / A
		approaches and data sources used to estimate	N/A

	Item		Reported on page No/
Section/item	No	Recommendation	line No
		resource use associated with model health states.	
		Describe primary or secondary research methods for	
		valuing each resource item in terms of its unit cost.	
		Describe any adjustments made to approximate to	
		opportunity costs.	
Currency, price date, and	14	Report the dates of the estimated resource quantities	10-14
conversion		and unit costs. Describe methods for adjusting	
		estimated unit costs to the year of reported costs if	
		necessary. Describe methods for converting costs into	
Choice of model		a common currency base and the exchange rate.	
	15	Describe and give reasons for the specific type of	N/A
		decision-analytical model used. Providing a figure to	
		show model structure is strongly recommended.	
Assumptions	16	Describe all structural or other assumptions	N/A
		underpinning the decision-analytical model.	
Analytical methods	17	Describe all analytical methods supporting the	10-14
		evaluation. This could include methods for dealing	
		with skewed, missing, or censored data; extrapolation	
		methods; methods for pooling data; approaches to	
		validate or make adjustments (such as half cycle	
		corrections) to a model; and methods for handling	
D lt		population heterogeneity and uncertainty.	
Results	10	Demonstration represent references and if used	10.21
Study parameters	18	Report the values, ranges, references, and, if used,	19-21
		probability distributions for all parameters. Report	
		reasons or sources for distributions used to represent	
		uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	
Incremental costs and	19	For each intervention, report mean values for the	19-21
outcomes	19	main categories of estimated costs and outcomes of	19-21
		interest, as well as mean differences between the	
		comparator groups. If applicable, report incremental	
		cost-effectiveness ratios.	
Characterising uncertainty	20a	Single study-based economic evaluation: Describe the	19-21
		effects of sampling uncertainty for the estimated	
		incremental cost and incremental effectiveness	
		parameters, together with the impact of	
		methodological assumptions (such as discount rate,	
		study perspective).	
	20b	Model-based economic evaluation: Describe the	N/A
		effects on the results of uncertainty for all input	
		parameters, and uncertainty related to the structure	
		of the model and assumptions.	
Characterising	21	If applicable, report differences in costs, outcomes, or	19-21
heterogeneity		cost-effectiveness that can be explained by variations	
		between subgroups of patients with different baseline	
		characteristics or other observed variability in effects	
		that are not reducible by more information.	
Discussion			
Study findings, limitations,	22	Summarise key study findings and describe how they	22-26
generalisability, and		support the conclusions reached. Discuss limitations	
current knowledge		and the generalisability of the findings and how the	
		findings fit with current knowledge.	
Other			
Source of funding	23	Describe how the study was funded and the role of	4

	Item		Reported on page No/
Section/item	No	Recommendation	line No
		the funder in the identification, design, conduct, and	
		reporting of the analysis. Describe other non-	
		monetary sources of support.	
Conflicts of interest	24	Describe any potential for conflict of interest of study	4-5
		contributors in accordance with journal policy. In the	
		absence of a journal policy, we recommend authors	
		comply with International Committee of Medical	
		Journal Editors recommendations.	

For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist